Discovery Labs Admits Pricing For Long-Awaited Surfaxin Will Be Tricky

Surfaxin, a synthetic alternative to animal-derived products for respiratory distress syndrome, deserves a premium, say execs, but company’s main goal is to get top spot on hospital formularies in competition with low-cost rivals.